BUZZ-Organogenesis falls after joint disease therapy fails to meet late-stage study goal** Shares of Organogenesis ORGO.O fall 11.1% to $4.16 in extended trade
** Company says its experimental therapy, ReNu, did not meet the main goal in its second late-stage trial for knee osteoarthritis, despite showing numerical improvement in pain reduction
** Knee osteoarthritis is a degenerative joint condition where the protective cartilage in the knee wears away, leading to pain, stiffness, swelling and a grinding or crackling sensation with movement
** As of last close, stock up 46.2% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments